Checklist for Prescribers v2 Tenofovir PrEP

Important safety information for individuals using PrEP v2

Important safety information for prescribers v2 Tenofovir PrEP

Reminder card v2 Tenofovir PrEP

Tenofovir HBV indications materials for children and adolescents

CHECKLIST FOR PRESCRIBERS Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

EMTRICITABINE/ TENOFOVIR DISOPROXIL FOR PrEP REMINDER CARD

IMPORTANT SAFETY INFORMATION For Prescribers About emtricitabine/ tenofovir disoproxil for a Pre-Exposure Prophylaxis (PrEP) Indication

IMPORTANT INFORMATION ABOUT EMTRICITABINE/TENOFOVIR DISOPROXIL TO REDUCE THE RISK OF GETTING HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION Information for individuals who have been prescribed emtricitabine/ tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

Emtricitabine-Tenofovir Checklist for Prescribers-v2.0

Important educational information for Patients

Important safety information for prescribers-v2.0

Patient Reminder card-v2.0

Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP) Complete checklist at each visit and file in individuals medical record.

Renal and bone effects risk minimisation material: Tenofovir disoproxil for children and adolescents with HIV-1

Information for individuals who have been prescribed emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

Emtricitabine/ tenofovir disoproxil is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. This indication is based on clinical trials in men who have sex with men (MSM) at high risk for HIV-1 infection and on men and women in heterosexual serodiscordant couples.

You have been prescribed emtricitabine/ tenofovir disoproxil for PrEP (pre-exposure prophylaxis) to help reduce the risk of getting HIV-1 infection. For this medicine to work effectively it is important that you don’t miss doses. The recommended dose is one emtricitabine/ tenofovir disoproxil tablet each day. Take emtricitabine/ tenofovir disoproxil exactly as your doctor has told you.

Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

Information for individuals who have been prescribed emtricitabine/ tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

For Prescribers About emtricitabine/ tenofovir disoproxil for a Pre-Exposure Prophylaxis (PrEP) Indication

EMTRICITABINE/ TENOFOVIR DISOPROXIL FOR PrEP REMINDER CARD

Emtricitabine/Tenofovir disoproxil Checklist for Prescribers PrEP

Patient Brochure for Emtricitabine/Tenofovir disoproxil for PrEP (pre-exposure prophylaxis)

Important Safety Information for Prescribers About Emtricitabine/Tenofovir Disoproxil for a Pre-exposure Prophylaxis (PrEP) Indication

Patient Reminder Card for Emtricitabine/Tenofovir disoproxil for PrEP (pre-exposure prophylaxis).

Checklist for Prescribers

Information for individuals who have been prescribed emtricitabine/ tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)

For Prescribers About emtricitabine/ tenofovir disoproxil for a Pre-Exposure Prophylaxis (PrEP) Indication

EMTRICITABINE/ TENOFOVIR DISOPROXIL FOR PrEP REMINDER CARD

Renal risk minimisation material: Tenofovir disoproxil for adolescent children with chronic hepatitis B

Renal and bone effects risk minimisation material: Tenofovir disoproxil for children and adolescents with HIV-1

RENAL RISK MINIMISATION MATERIAL: TENOFOVIR DISOPROXIL FOR ADOLESCENT CHILDREN WITH CHRONIC HEPATITIS B

RENAL AND BONE EFFECTS RISK MINIMISATION MATERIAL: TENOFOVIR DISOPROXIL FOR CHILDREN AND ADOLESCENTS WITH HIV-1

HIV-1 Renal & bone effects education brochure - children

HBV renal education brochure - children

This brochure provides important advice on the management of potential renal and bone effects of tenofovir disoproxil in HIV-1 infected children and adolescents aged 2 to <18 years, and on the dosing recommendations for tenofovir disoproxil in this population.

This brochure provides important advice on the management of potential renal and bone effects of tenofovir disoproxil in adolescent patients with chronic hepatitis B aged 12 to <18 years, and on the dosing recommendations for tenofovir disoproxil in this population.

RENAL RISK MINIMISATION MATERIAL: TENOFOVIR DISOPROXIL FOR ADULTS WITH CHRONIC HEPATITIS B

Checklist For Prescribers from the Physician educational pack for Truvada® (emtricitabine 200mg/ tenofovir disoproxil fumarate 245mg) for pre-exposure prophylaxis (PrEP) in patients at risk of sexually acquired HIV-1 infection

Patient Leaflet from the Physician educational pack for Truvada® (emtricitabine 200mg/ tenofovir disoproxil fumarate 245mg) for pre-exposure prophylaxis (PrEP) in patients at risk of sexually acquired HIV-1 infection. It contains Important Information About Truvada® (emtricitabine/tenofovir disoproxil fumarate) to Reduce the Risk of Getting Human Immunodeficiency Virus (HIV) Infection for individuals who have been prescribed Truvada® for Pre-Exposure Prophylaxis (PrEP)

Important Safety Information for Prescribers About Truvada® (emtricitabine/tenofovir disoproxil fumarate) for a Pre-exposure Prophylaxis (PrEP) Indication

Reminder Card for patients from the Physician educational pack for Truvada® (emtricitabine 200mg/ tenofovir disoproxil fumarate 245mg) for pre-exposure prophylaxis (PrEP) in patients at risk of sexually acquired HIV-1 infection.